Eplerenone
Eplerenone, sold as Inspra, is an aldosterone antagonist, a medicine taken by mouth. The US label read, for Inspra tablets, lists two uses in adults: improving survival in stable people who have symptomatic heart failure with reduced ejection fraction (40% or less) after a heart attack, and the treatment of high blood pressure to lower it.
Also called Inspra
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 298869; UNII 6995V82D0B. MeSH descriptor D000077545 is Eplerenone. Class: Aldosterone Antagonist (FDA established pharmacologic class, RxClass). The label read is the Viatris Specialty LLC label for Inspra tablets, application NDA021437, effective 2025-06-23 in openFDA. Generic eplerenone labels were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone.
Claims and evidence
Context Adults with heart failure with reduced ejection fraction after a heart attack, and adults with hypertension, as described in the US label of Inspra tablets
- Recipient
- Adult
- Population
- Stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and adults with hypertension, as the indications section of the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction
- Adults with hypertension
- Excluded
- None stated
The US label of Inspra (eplerenone tablets, Viatris Specialty LLC, application NDA021437; the version dated 2025-06-23 in openFDA) describes eplerenone as an aldosterone antagonist. It lists improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and the treatment of hypertension in adults, to lower blood pressure.
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-06-23
- Source state
- Current
- Version fingerprint
5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Heart Failure Post-Myocardial Infarction
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-06).
- Retrieved
- Source effective date
- 2025-06-23
- Source state
- Current
- Version fingerprint
5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.2 Hypertension
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2025-06-23
- Source state
- Current
- Version fingerprint
5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250623.
- Retrieved
- Source effective date
- 2025-06-23
- Source state
- Current
- Version fingerprint
5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists improving survival in stable adults with symptomatic heart failure with reduced ejection fraction after an acute myocardial infarction as an indication: Heart failure with reduced ejection fraction (HFrEF)
The US label of Inspra (eplerenone tablets, Viatris Specialty LLC, application NDA021437; the version dated 2025-06-23 in openFDA) describes eplerenone as an aldosterone antagonist. It lists improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and the treatment of hypertension in adults, to lower blood pressure.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists heart failure after an acute myocardial infarction as the setting of its first indication: Heart attack (myocardial infarction)
The US label of Inspra (eplerenone tablets, Viatris Specialty LLC, application NDA021437; the version dated 2025-06-23 in openFDA) describes eplerenone as an aldosterone antagonist. It lists improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and the treatment of hypertension in adults, to lower blood pressure.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists the treatment of hypertension in adults as an indication: Hypertension (high blood pressure)
The US label of Inspra (eplerenone tablets, Viatris Specialty LLC, application NDA021437; the version dated 2025-06-23 in openFDA) describes eplerenone as an aldosterone antagonist. It lists improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and the treatment of hypertension in adults, to lower blood pressure.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:eplerenone- Content hash
4612b467615436888490472bfc6632488a260a40e454e5ad3a1a476556a66950